

## SGN-ALPV

An investigational antibody-drug conjugate directed to ALPP and/or ALPPL2

### Anti-ALPP/ALPPL2 antibody

Fully human IgG1 monoclonal antibody that binds to ALPP and/or ALPPL2

### Key Attribute

Capable of binding dimers of ALPP and/or ALPPL2

### Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent within the target cell

### MMAE

Microtubule-disrupting agent

### Targets: ALPP and/or ALPPL2

- Alkaline phosphatases that share high protein sequence similarity and play key roles in nucleotide recycling<sup>1,2</sup>
- Highly expressed in solid tumors including ovarian, testicular, germ cell, and endometrial cancers, as well as in a subpopulation of lung and gastric cancers<sup>3-6</sup>
- Normal tissue expression is restricted to the placenta, reproductive tissues, and lung<sup>3-6</sup>

### Proposed Mechanism of Action<sup>7,a</sup>

- Direct cytotoxicity
- Bystander effect
- Antibody-dependent cellular cytotoxicity
- Antibody-dependent cellular phagocytosis
- Immunogenic cell death


**ALPP:** alkaline phosphatase placental; **ALPPL2:** alkaline phosphatase placental-like 2; **mc-vc:** maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E

<sup>a</sup>Based on preclinical data

1. Su Y et al. Cancer Res. 2020; 4552-64. 2. Zimmermann H et al. Purinergic Signal. 2012; 437-502. 3. Ravenni N et al. MAbs. 2013; 86-94. 4. Dua P et al. Cancer Res. 2013; 1934-45. 5. Albrecht W et al. J Lab Med. 2004; 109-15. 6. Nouwen EJ et al. Cancer Res. 1986; 866-76. 7. Data on file.


**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**





Proposed Mechanism of Action<sup>1,a,b</sup>

- 1 Binds to ALPP/ALPPL2 homodimers
- 2 Complex internalization and trafficking
- 3 MMAE release
- 4 Microtubule disruption
- 5 Cell cycle arrest and apoptotic cell death



**ALPP:** alkaline phosphatase placental; **ALPPL2:** alkaline phosphatase placental-like 2; **MMAE:** monomethyl auristatin E; **NK:** natural killer

<sup>a</sup>Based on preclinical data

<sup>b</sup>Binding may also occur between 1 or 2 molecules of SGN-ALPV and the homo/heterodimers of ALPP and ALPPL2

<sup>c</sup>Additional mechanisms of action and their potential to complement the direct cytotoxicity of some MMAE-based antibody-drug conjugates are currently under investigation.

1. Data on file.

Clinical Trials



RECRUITING

SGNALPV-001: Advanced solid tumors  
(NCT05229900) SGN-ALPV

Phase 1      Phase 2      Phase 3

Clinical trial information retrieved from [clinicaltrials.gov](https://clinicaltrials.gov), accessed Apr 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.